SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Welcome to the GENT board. GENT has the first drug for VOD.
An SI Board Since July 2006
Posts SubjectMarks Bans Symbol
408 17 0 GENT
Emcee:  rareearth42 Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
258Gentium Reports Fourth Quarter and Year End 2012 Financial Results [graphic]PresIRWIN JAMES FRANKEL-3/28/2013
257ebmt.org The European Group for Blood and Marrow Transplantation expresses its IRWIN JAMES FRANKEL23/22/2013
256Thanks to ghmm: ema.europa.eu I was not aware of the kidney issue. Comments wIRWIN JAMES FRANKEL-3/22/2013
255>> I wonder if the EMA often reverses its opinion upon reflection and new IRWIN JAMES FRANKEL-3/22/2013
254Very low volume at the new low prices. I wonder if the EMA often reverses its opaul ta-3/22/2013
253I should have posted this one - Gentium Receives Negative Opinion From the CHMIRWIN JAMES FRANKEL-3/22/2013
252Gentium Provides Update on the Review of Defibrotide Marketing Authorization [grIRWIN JAMES FRANKEL-3/22/2013
251Wedbush, outperform, pt 14 - suggests company will increase pricingIRWIN JAMES FRANKEL-2/22/2013
250Brean Capital retains Buy and PT of 16 - defends the stock.IRWIN JAMES FRANKEL-2/21/2013
249The market will not understand this one. But with unit sales rising 40% year-ovIRWIN JAMES FRANKEL-2/21/2013
248Well when the CHMP response is given at least we will know what the issue(s) areghmm-2/21/2013
247Gentium Provides Update on the Review of Defibrotide Marketing Authorization [grIRWIN JAMES FRANKEL-2/21/2013
246If anyone is wondering why the higher volume all of a sudden siliconinvestor.comghmm-2/6/2013
245Gentium Provides an Update on Defibrotide MAA to EMA [graphic]Press Release: GenIRWIN JAMES FRANKEL-1/17/2013
244I can't tell what they are "going for". The hope is that the EU iIRWIN JAMES FRANKEL-12/18/2012
243I've wondered (maybe hoped) that part of the back and forth is they are goinghmm-12/18/2012
242VILLA GUARDIA, Italy, Dec. 18, 2012 (GLOBE NEWSWIRE) -- Gentium S.p.A. ( GENT) (IRWIN JAMES FRANKEL-12/18/2012
241Results From Gentium's Treatment IND for Defibrotide Presented at the AmericIRWIN JAMES FRANKEL-12/13/2012
240ash.confex.com Comparisons are to historical. N = 333 and of that 274 sVODIRWIN JAMES FRANKEL-12/8/2012
239The abstracts: ash.confex.com ash.confex.com ash.confex.comIRWIN JAMES FRANKEL-12/8/2012
238Data From Non HSCT VOD Patients Treated With Defibrotide and a Treatment IND UpdIRWIN JAMES FRANKEL-12/7/2012
237Gentium To Initiate Clinical Development in Japan and Expand Named-Patient ProgrIRWIN JAMES FRANKEL-12/5/2012
236Thanks for posting! By the time they get things worked out I wonder if things wghmm-12/2/2012
235>> Hard to believe that they think chances of disapproval in Europe are 35IRWIN JAMES FRANKEL112/1/2012
234Thanks for that post IJ. Hard to believe that they think chances of disapprovalfred hayes112/1/2012
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News